Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

KMT9 controls growth and stemness of colorectal cancer

ABSTRACT: KMT9 controls growth and stemness of colorectal cancer

PROVIDER: PRJNA632605 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR11786400_1.fastq.gz	Fastqsanger.gz
	SRR11786400_2.fastq.gz	Fastqsanger.gz
	SRR11786401_1.fastq.gz	Fastqsanger.gz
	SRR11786401_2.fastq.gz	Fastqsanger.gz
	SRR11786402_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 156

Similar Datasets

KMT9 controls growth and stemness of colorectal cancer [RNA-Seq]

Project description:KMT9 controls growth and stemness of colorectal cancer [RNA-Seq]

| PRJNA632610 | ENA

KMT9 controls growth and stemness of colorectal cancer [ChIP-seq]

Project description:KMT9 controls growth and stemness of colorectal cancer [ChIP-seq]

| PRJNA632609 | ENA

KMT9 controls growth and stemness of colorectal cancer [single-cell RNA-seq]

Project description:KMT9 controls growth and stemness of colorectal cancer [single-cell RNA-seq]

| PRJNA632611 | ENA

KMT9 controls growth and stemness of colorectal cancer

Project description:This SuperSeries is composed of the SubSeries listed below.

2021-11-29 | GSE150506 | GEO

Mitochondrial KMT9 methylates DLAT to control pyruvate dehydrogenase activity, de novo lipogenesis, and prostate cancer growth

Project description:Prostate cancer (PCa) growth depends on de novo lipogenesis controlled by the mitochondrial pyruvate dehydrogenase complex (PDC). In this study, we identified lysine methyltransferase (KMT)9 as a novel regulator of PDC activity. KMT9 is localized in mitochondria of PCa cells, but not in mitochondria of other tumor cell types. Mitochondrial KMT9 regulates PDC activity by monomethylation of its subunit dihydrolipoamide transacetylase (DLAT) at lysine 596. Depletion of KMT9 compromises PDC activity, de novo lipogenesis, and PCa cell proliferation, which can be rescued with exogenous KMT9 targeted to mitochondria. Similarly, comparable defects caused by DLAT depletion can be rescued with exogenous DLAT, but not with a methylation-defective DLAT mutant. Concomitant chemical inhibition of de novo lipogenesis and KMT9 depletion more efficiently impair PCa cell proliferation than either treatment alone. Importantly, KMT9 controls PDC activity, de novo lipogenesis, and tumor growth in a PCa mouse model. Finally, in human patients, levels of mitochondrial KMT9 and DLAT K596me1 correlate with Gleason grade. Together, we present a novel mechanism of PDC regulation and the first example of a histone methyltransferase with nuclear and mitochondrial functions. The exceptional dependency on mitochondrial KMT9 allows to develop novel therapeutic strategies to fight PCa.

2024-12-03 | PXD053942 | Pride

KMT9 controls growth and stemness of colorectal cancer [RNA-Seq]

Project description:The aim of the study is to identify KMT9α target genes in AOM/DSS tumour organoids, APK and APKK organoids, patient derived CRC organoids, AOM/DSS mouse tumours and normal mouse colon

2021-11-29 | GSE150503 | GEO

KMT9 controls growth and stemness of colorectal cancer [ChIP-seq]

Project description:The aim of the study is to identify KMT9a target genes in AOMDSS tumour organoids

2021-11-29 | GSE150502 | GEO

ATF6 promotes colorectal cancer growth and stemness by regulating the Wnt pathway

Project description:The unfolded protein response (UPR) maintains endoplasmic reticulum (ER) homeostasis by sensing protein-folding stress and orchestrating cellular adaptation via the ER-transmembrane proteins IRE1, PERK and ATF6. Malignant cells can co-opt UPR signaling by IRE1 and PERK to sustain tumor growth; however, the importance of ATF6 in cancer remains poorly deciphered. We observed elevated ATF6 transcriptional activity in several cancers including colorectal carcinoma (CRC). Genetic silencing or small molecule inhibition of ATF6 blocked cell cycle progression and reduced viability of several human CRC cell lines in vitro and disrupted tumor progression in vivo. Unexpectedly, ATF6 interference also disabled Myc and Wnt signaling and reduced stemness. ATF6 inhibition attenuated growth of organoids derived from malignant but not normal human intestinal tissue, reducing Wnt-pathway activity and driving cellular differentiation. Wnt-surrogate agonism rescued the growth inhibitory phenotype of ATF6 interference. Our findings identify ATF6 as an unexpected facilitator of oncogenic Wnt signaling in CRC.

2024-08-12 | MSV000095581 | MassIVE

KMT9 controls growth and stemness of colorectal cancer [single-cell RNA-seq]

Project description:The aim of the study is to identify cell-specific KMT9a target genes in AOMDSS tumour organoids

2021-11-29 | GSE150505 | GEO

ATF6 promotes colorectal cancer growth and stemness by regulating the Wnt pathway

Project description:ATF6 promotes colorectal cancer growth and stemness by regulating the Wnt pathway

| PRJNA1144418 | ENA